MeMed Diagnostics Ltd (MeMed) is a developer of diagnostic solutions for inflammatory and infectious diseases. The company’s products include ImmunoXpert which is an in-vitro diagnostic test used for diagnosing the difference between bacterial and viral infections. It provides ImmunoPoC, a hand-held instrument used for the diagnosis of bacterial versus viral infections. MeMed offers services in varied fields including molecular immunology, clinical infectious diseases, informatics and in vitro diagnostics. The company uses its technology to discover, develop and validate novel diagnostic solutions. It partners with various academic, clinical and commercial partners. The company operates through its manufacturing and research and development facilities in Israel. MeMed is headquartered in Tirat Carmel, Israel.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company MeMed Diagnostics Ltd
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
MeMed Diagnostics Ltd Company Overview
MeMed Diagnostics Ltd Company Snapshot
MeMed Diagnostics Ltd Pipeline Products and Ongoing Clinical Trials Overview
MeMed Diagnostics Ltd - Major Products and Services
MeMed Diagnostics Ltd Pipeline Products by Development Stage
MeMed Diagnostics Ltd Pipeline Products Overview
Diagnostic Test - COVID-19
Diagnostic Test - COVID-19 Product Overview
ImmunoPoC
ImmunoPoC Product Overview
MeMed Alert
MeMed Alert Product Overview
MeMed COVID-19 Severity Test
MeMed COVID-19 Severity Test Product Overview
MeMed ImmnuoRNA
MeMed ImmnuoRNA Product Overview
MeMed Neo
MeMed Neo Product Overview
MeMed Sepsis
MeMed Sepsis Product Overview
MeMed Ultra Flu
MeMed Ultra Flu Product Overview
MeMed Diagnostics Ltd - Key Competitors
MeMed Diagnostics Ltd - Key Employees
MeMed Diagnostics Ltd - Locations And Subsidiaries
Head Office
Recent Developments
MeMed Diagnostics Ltd, Recent Developments
Nov 06, 2023: MeMed Bolsters Leadership Team With Appointment of Ori Hadomi as Chairman and Peter Scheu as President of MeMed US
Oct 24, 2023: MeMed awarded US BARDA Contract to Demonstrate Clinical Utility of the FDA-Cleared MeMed BV Test for Distinguishing Bacterial From Viral infections
Jul 20, 2023: FDA grants 510(k) clearance for MeMed BV test on whole blood samples
Jul 19, 2023: MeMed: FDA Clears Pioneering MeMed BV Test Direct From Whole Blood Allowing Faster Time To Result And Broader Patient Access When Distinguishing Bacterial From Viral Infections
Jan 31, 2023: Beckman Coulter and MeMed to Expand Access to Proven Host Immune Response Diagnostic Able to Distinguish Between Bacterial and Viral Infections
Dec 22, 2022: Tulsa ER & Hospital adopts trailblazing MeMed BV Test